Huakang Biomedical Holdings Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chunguang Zhang

Chief Executive Officer (CEO)

CN¥703.0k

Compensación total

Porcentaje del salario del CEO	44.7%
Permanencia del CEO	7.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	4.7yrs

Actualizaciones recientes de la dirección

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

Recent updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chunguang Zhang en comparación con los beneficios de Huakang Biomedical Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CN¥6m
Mar 31 2024	n/a	n/a	-CN¥6m
Dec 31 2023	CN¥703k	CN¥314k	-CN¥6m
Sep 30 2023	n/a	n/a	-CN¥5m
Jun 30 2023	n/a	n/a	-CN¥4m
Mar 31 2023	n/a	n/a	-CN¥3m
Dec 31 2022	CN¥689k	CN¥308k	-CN¥3m
Sep 30 2022	n/a	n/a	-CN¥2m
Jun 30 2022	n/a	n/a	-CN¥3m
Mar 31 2022	n/a	n/a	-CN¥4m
Dec 31 2021	CN¥399k	CN¥271k	-CN¥4m
Sep 30 2021	n/a	n/a	-CN¥7m
Jun 30 2021	n/a	n/a	-CN¥8m
Mar 31 2021	n/a	n/a	-CN¥10m
Dec 31 2020	CN¥727k	CN¥250k	-CN¥12m
Sep 30 2020	n/a	n/a	-CN¥9m
Jun 30 2020	n/a	n/a	-CN¥7m
Mar 31 2020	n/a	n/a	-CN¥3m
Dec 31 2019	CN¥349k	CN¥227k	-CN¥284k
Sep 30 2019	n/a	n/a	-CN¥3m
Jun 30 2019	n/a	n/a	-CN¥2m
Mar 31 2019	n/a	n/a	-CN¥377k
Dec 31 2018	CN¥284k	CN¥234k	-CN¥459k
Dec 31 2017	CN¥243k	CN¥183k	-CN¥2m

Compensación vs. Mercado: La compensación total de Chunguang($USD98.09K) está por debajo de la media de empresas de tamaño similar en el mercado Hong Kong ($USD235.49K).

Compensación vs. Ingresos: La compensación de Chunguang ha aumentado mientras la empresa no es rentable.

CEO

Chunguang Zhang (56 yo)

7.1yrs

Permanencia

CN¥703,000

Compensación

Mr. Chunguang Zhang is Chief Executive officer at Huakang Biomedical Holdings Company Limited. Mr. Zhang is mainly responsible for business operations and the day-to-day management of Group. Mr. Zhang has...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Shuguang Zhang	Chairman of the Board	7.1yrs	CN¥479.00k	27.71% CN¥ 27.3m
Chunguang Zhang	CEO & Executive Director	7.1yrs	CN¥703.00k	sin datos
Lai Yin Poon	CFO, Compliance Officer & Executive Director	7.1yrs	CN¥769.00k	0.80% CN¥ 788.0k
Jiaming He	Business Development Director & Executive Director	4.7yrs	CN¥484.00k	sin datos
Faat Ting Cheng	Independent Non Executive Director	4yrs	CN¥90.00k	sin datos
Yim Yang Chang	Vice Chairman of King Grace Company Limited	no data	sin datos	sin datos
Kwok Fai Chow	Independent Non-Executive Director	3.8yrs	CN¥90.00k	sin datos
Ching Man Chow	Independent Non-Executive Director	1.1yrs	CN¥38.00k	sin datos

4.7yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de 8622 se considera experimentada (4.4 años de antigüedad promedio).

Huakang Biomedical Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Chairman of the Board recently sold HK$815k worth of stock

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Recent updates

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.004 loss in 1H 2023)

Huakang Biomedical Holdings Company Limited to Report First Half, 2024 Results on Aug 16, 2024

New minor risk - Share price stability

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.007 million.

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 3.224 million.

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 5.952 million.

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

New minor risk - Shareholder dilution

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

Chairman of the Board recently sold HK$815k worth of stock

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 8.61 million.

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022)

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 1Q 2022)

Full year 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.011 loss in FY 2021)

Vice Chairman recently sold HK$101k worth of stock

Less than half of directors are independent

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.60496 million.

Second quarter 2022 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 2Q 2021)

Huakang Biomedical Holdings Company Limited to Report First Half, 2022 Results on Aug 08, 2022

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 17, 2022

First quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.003 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.029 loss in FY 2020)

Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021

Third quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.001 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.008 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.003 loss per share (vs CN¥0.007 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.029 loss per share (vs CN¥0.001 loss in FY 2019)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

Huakang Biomedical Holdings Company Limited Announces Management Changes

Third quarter 2020 earnings released: CN¥0.001 loss per share

Huakang Biomedical Holdings Company Limited to Report Q3, 2020 Results on Nov 10, 2020

Earnings released

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad